Published in Blood on July 13, 2004
Rituximab for steroid-refractory chronic graft-versus-host disease. Blood (2006) 3.08
Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) (2009) 2.35
Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood (2011) 2.33
Towards a rational graft-versus-host disease (GVHD) prophylaxis: rituximab should not be forgotten. Haematologica (2013) 1.40
New approaches for preventing and treating chronic graft-versus-host disease. Blood (2005) 1.20
Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study. Haematologica (2010) 1.16
Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. Blood (2013) 1.14
Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation. Br J Haematol (2009) 1.07
Current and future approaches for control of graft-versus-host disease. Expert Rev Hematol (2008) 0.95
A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation. Clin Cancer Res (2015) 0.92
Association of mixed hematopoietic chimerism with elevated circulating autoantibodies and chronic graft-versus-host disease occurrence. Transplantation (2006) 0.90
Rituximab: a review of dermatological applications. J Clin Aesthet Dermatol (2009) 0.89
Pharmacokinetics and pharmacodynamics of ASKP1240, a fully human anti-CD40 antibody, in normal and renal transplanted Cynomolgus monkeys. Transplantation (2014) 0.84
Effectiveness of subcutaneous low-dose alemtuzumab and rituximab combination therapy for steroid-resistant chronic graft-versus-host disease. Haematologica (2011) 0.83
The immunological phenotype of rituximab-sensitive chronic graft-versus-host disease: a phase II study. Haematologica (2011) 0.83
Therapy of chronic graft-versus-host disease. Best Pract Res Clin Haematol (2008) 0.81
B-cell-directed therapy for chronic graft-versus-host disease. Haematologica (2010) 0.81
Understanding chronic GVHD from different angles. Biol Blood Marrow Transplant (2012) 0.78
Tirosin kinase inhibitors in chronic graft versus host disease: from bench to bedside. ScientificWorldJournal (2011) 0.78
B-cell-mediated strategies to fight chronic allograft rejection. Front Immunol (2013) 0.77
Rippled skin, fasciitis, and joint contractures. J Am Acad Dermatol (2008) 0.75
High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med (2009) 4.90
Cytarabine dose for acute myeloid leukemia. N Engl J Med (2011) 4.15
Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood (2002) 3.56
Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol (2005) 3.15
The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood (2008) 2.35
High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol (2013) 2.22
Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy. Circulation (2014) 2.16
High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood (2002) 2.01
Human regulatory T cells control xenogeneic graft-versus-host disease induced by autologous T cells in RAG2-/-gammac-/- immunodeficient mice. Clin Cancer Res (2006) 1.84
Allogeneic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome who have chromosome 5 and/or 7 abnormalities. Haematologica (2005) 1.75
High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. J Clin Oncol (2010) 1.64
Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood (2007) 1.60
Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. J Clin Oncol (2012) 1.60
Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON-SAKK co-operative group studies. Br J Haematol (2005) 1.54
Chronic kidney disease after myeloablative allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2007) 1.50
Preferential HLA-DRB1*11-dependent presentation of CUB2-derived peptides by ADAMTS13-pulsed dendritic cells. Blood (2013) 1.49
The association of CD25 expression on donor CD8+ and CD4+ T cells with graft-versus-host disease after donor lymphocyte infusions. Haematologica (2005) 1.49
Elevated levels of D-dimer and fragment 1+2 upon central venous catheter insertion and factor V Leiden predict subclavian vein thrombosis. Haematologica (2005) 1.47
The macrophage mannose receptor promotes uptake of ADAMTS13 by dendritic cells. Blood (2012) 1.46
Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol (2006) 1.42
Thrombocytopenia and release of activated von Willebrand Factor during early Plasmodium falciparum malaria. J Infect Dis (2007) 1.42
NOD2/CARD15 variants are not a risk factor for clinical outcome after nonmyeloablative allogeneic stem cell transplantation. Biol Blood Marrow Transplant (2011) 1.41
The spacer domain of ADAMTS13 contains a major binding site for antibodies in patients with thrombotic thrombocytopenic purpura. Thromb Haemost (2005) 1.39
A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B. Blood (2005) 1.35
Cladribine therapy for systemic mastocytosis. Blood (2003) 1.34
A brief history of pathology: Preface to a forthcoming series that highlights milestones in the evolution of pathology as a discipline. Virchows Arch (2010) 1.32
Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories. J Clin Oncol (2012) 1.30
An autoantibody epitope comprising residues R660, Y661, and Y665 in the ADAMTS13 spacer domain identifies a binding site for the A2 domain of VWF. Blood (2009) 1.27
ADAMTS13 deficiency with elevated levels of ultra-large and active von Willebrand factor in P. falciparum and P. vivax malaria. Am J Trop Med Hyg (2009) 1.27
The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients. Blood (2003) 1.26
C-reactive protein is a risk indicator for atrial fibrillation after myocardial revascularization. Ann Thorac Surg (2005) 1.23
Unison or cacophony: postgraduate training in pathology in Europe. Virchows Arch (2009) 1.21
FDG PET/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and meta-analysis. Eur J Nucl Med Mol Imaging (2013) 1.17
The pathology of bone marrow failure. Histopathology (2010) 1.16
The presence of active von Willebrand factor under various pathological conditions. Curr Opin Hematol (2007) 1.16
Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation. Blood (2005) 1.14
Amino acid regions 572-579 and 657-666 of the spacer domain of ADAMTS13 provide a common antigenic core required for binding of antibodies in patients with acquired TTP. Thromb Haemost (2006) 1.13
The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood (2004) 1.11
Whole-body MRI, including diffusion-weighted imaging, for the initial staging of malignant lymphoma: comparison to computed tomography. Invest Radiol (2009) 1.11
Rituximab treatment before reduced-intensity conditioning transplantation associates with a decreased incidence of extensive chronic GVHD. Biol Blood Marrow Transplant (2009) 1.08
High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma - results of a comprehensive meta-analysis. Cancer Treat Rev (2007) 1.07
Newly diagnosed lymphoma: initial results with whole-body T1-weighted, STIR, and diffusion-weighted MRI compared with 18F-FDG PET/CT. AJR Am J Roentgenol (2011) 1.07
Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. Blood (2010) 1.07
Allogeneic stem-cell transplantation for blastic plasmacytoid dendritic cell neoplasm. J Clin Oncol (2012) 1.06
Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants. Clin Microbiol Rev (2003) 1.06
Thrombocytopenia in early malaria is associated with GP1b shedding in absence of systemic platelet activation and consumptive coagulopathy. Br J Haematol (2010) 1.04
Residues Arg568 and Phe592 contribute to an antigenic surface for anti-ADAMTS13 antibodies in the spacer domain. Haematologica (2011) 1.02
Autologous peripheral blood stem cell transplantation for acute myeloid leukemia. Blood (2011) 1.01
A randomized multicenter comparison of CD34(+)-selected progenitor cells from blood vs from bone marrow in recipients of HLA-identical allogeneic transplants for hematological malignancies. Exp Hematol (2003) 1.01
Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood (2002) 0.99
Imbalance of angiopoietin-1 and angiopoetin-2 in severe dengue and relationship with thrombocytopenia, endothelial activation, and vascular stability. Am J Trop Med Hyg (2012) 0.98
Forced overexpression of either of the two common human Foxp3 isoforms can induce regulatory T cells from CD4(+)CD25(-) cells. Eur J Immunol (2008) 0.97
Risk factors for thromboembolic complications in inflammatory bowel disease: the role of hyperhomocysteinaemia. Dig Dis Sci (2005) 0.95
Severe dengue is associated with consumption of von Willebrand factor and its cleaving enzyme ADAMTS-13. PLoS Negl Trop Dis (2012) 0.94
Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma. Am J Hematol (2014) 0.92
Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia. Blood (2008) 0.92
Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma. Haematologica (2007) 0.92
Plasma concentration of von Willebrand factor predicts mortality in patients on chronic renal replacement therapy. Nephrol Dial Transplant (2011) 0.92
Antithymocyteglobulin as prophylaxis of graft failure and graft-versus-host disease in recipients of partially T-cell-depleted grafts from matched unrelated donors: a dose-finding study. Exp Hematol (2003) 0.91
Levels of extra domain A containing fibronectin in human atherosclerotic plaques are associated with a stable plaque phenotype. Atherosclerosis (2007) 0.91
Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years. Biol Blood Marrow Transplant (2007) 0.90
Influence of cytomegalovirus seropositivity on outcome after T cell-depleted bone marrow transplantation: contrasting results between recipients of grafts from related and unrelated donors. Clin Infect Dis (2002) 0.90
beta2-Glycoprotein I inhibits von Willebrand factor dependent platelet adhesion and aggregation. Blood (2007) 0.90
On the added value of baseline FDG-PET in malignant lymphoma. Mol Imaging Biol (2009) 0.89
Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Br J Haematol (2009) 0.89
Endothelial cell activation and hypercoagulability in ocular Behçet's disease. Am J Ophthalmol (2004) 0.88
Acute renal failure after nonmyeloablative stem cell transplantation in adults. Biol Blood Marrow Transplant (2008) 0.88
Extra-domain-A fibronectin: a new marker of fibrosis in cutaneous graft-versus-host disease. J Invest Dermatol (2004) 0.88
Whole-body MRI, including diffusion-weighted imaging, for staging lymphoma: comparison with CT in a prospective multicenter study. J Magn Reson Imaging (2013) 0.88
Activation of hemostasis after coronary artery bypass grafting with or without cardiopulmonary bypass. Anesth Analg (2004) 0.87
Factor V Leiden in central venous catheter-associated thrombosis. Br J Haematol (2002) 0.86
Platelet activation determines angiopoietin-1 and VEGF levels in malaria: implications for their use as biomarkers. PLoS One (2013) 0.86
A compulsory examination in pathology: redundant or necessary? Virchows Arch (2012) 0.86
Activating KIRs exert a crucial role on relapse and overall survival after HLA-identical sibling transplantation. Mol Immunol (2008) 0.86
Endothelial cell activation after subarachnoid hemorrhage. Neurosurgery (2002) 0.85
IL-18 serum concentration is markedly elevated in acute EBV infection and can serve as a marker for disease severity. J Infect Dis (2012) 0.85
Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM. J Clin Oncol (2003) 0.84
Prognostic relevance of immunohistochemical subclassification of diffuse large B-cell lymphoma in two prospective phase III clinical trials. Clin Lymphoma Myeloma Leuk (2011) 0.84
Results of hematopoietic stem cell transplantation after treatment with different high-dose total-body irradiation regimens in five Dutch centers. Int J Radiat Oncol Biol Phys (2008) 0.84
Magnetic resonance imaging of malignant lymphoma. Expert Rev Hematol (2011) 0.84
Cataract after total body irradiation and bone marrow transplantation: degree of visual impairment. Int J Radiat Oncol Biol Phys (2002) 0.83
ADC measurements in the evaluation of lymph nodes in patients with non-Hodgkin lymphoma: feasibility study. MAGMA (2010) 0.83
Effect of antithymocyte globulin on quantitative immune recovery and graft-versus-host disease after partially T-cell-depleted bone marrow transplantation: a comparison between recipients of matched related and matched unrelated donor grafts. Transplantation (2003) 0.82
Detection of the JAK2V617F mutation in patients with slightly elevated platelets or hemoglobin without a secondary cause. Ann Hematol (2007) 0.82
Cardiomyocyte death in patients with end-stage heart failure before and after support with a left ventricular assist device: low incidence of apoptosis despite ubiquitous mediators. J Heart Lung Transplant (2003) 0.82
Bone marrow biopsy in diffuse large B-cell lymphoma: useful or redundant test? Acta Oncol (2014) 0.82
Whole-body magnetic resonance imaging, including diffusion-weighted imaging, for diagnosing bone marrow involvement in malignant lymphoma. Br J Haematol (2010) 0.81
Potential prognostic implications of whole-body bone marrow MRI in diffuse large B-cell lymphoma patients with a negative blind bone marrow biopsy. J Magn Reson Imaging (2013) 0.81
Magnetic resonance imaging for the detection of bone marrow involvement in malignant lymphoma. Br J Haematol (2008) 0.81
Whole-body MRI for the detection of bone marrow involvement in lymphoma: prospective study in 116 patients and comparison with FDG-PET. Eur Radiol (2013) 0.81